Are you asking about experiences with thalidomide 50mg as maintenance therapy after an autologous stem cell transplant (ASCT)?
While thalidomide was historically used for myeloma maintenance, it's now considered less favorable compared to newer options. The main concerns are toxicity and the risk of peripheral neuropathy Show Full Answer
Are you asking about experiences with thalidomide 50mg as maintenance therapy after an autologous stem cell transplant (ASCT)?
While thalidomide was historically used for myeloma maintenance, it's now considered less favorable compared to newer options. The main concerns are toxicity and the risk of peripheral neuropathy (nerve damage outside the brain and spinal cord).
Lenalidomide (Revlimid) has become the current standard for maintenance therapy after ASCT because it's generally better tolerated. Studies show it can keep myeloma in remission for around 57 months after transplant, compared to about 30 months without maintenance.
That said, a MyMyelomaTeam member shared being on maintenance thalidomide for nine years after their initial treatment. They did well on it, though they noted feeling nervous when eventually taken off the medication.
If you're currently on thalidomide maintenance, it's worth discussing with your oncologist whether this remains the best option for you, especially given the newer alternatives available. Your doctor can help weigh the benefits against potential side effects based on your specific situation.
March 10
Join
Your Privacy Choices
